Nephrotoxicity of Anti-Angiogenic Therapies - Université Paris-Est-Créteil-Val-de-Marne Access content directly
Journal Articles Diagnostics Year : 2021

Nephrotoxicity of Anti-Angiogenic Therapies


The use of inhibitors of vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor 2 (VEGFR2) signaling for the treatment of cancer has increased over the last decade. This signaling pathway plays a fundamental role in angiogenesis and also in kidney physiology. The emergence of anti-angiogenic therapies has led to adverse nephrotoxic effects, despite improving the outcomes of patients. In this review, we will present the different anti-angiogenic therapies targeting the VEGFR pathway in association with the incidence of renal manifestations during their use. In addition, we will discuss, in detail, the pathophysiological mechanisms of frequent renal diseases such as hypertension, proteinuria, renal dysfunction, and electrolyte disorders. Finally, we will outline the cellular damage described following these therapies.
Fichier principal
Vignette du fichier
diagnostics-11-00640.pdf (1.33 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03293690 , version 1 (21-07-2021)



Margaux van Wynsberghe, Joanne Flejeo, Hamza Sakhi, Mario Ollero, Dil Sahali, et al.. Nephrotoxicity of Anti-Angiogenic Therapies. Diagnostics, 2021, 11 (4), pp.640. ⟨10.3390/diagnostics11040640⟩. ⟨hal-03293690⟩
63 View
94 Download



Gmail Facebook X LinkedIn More